50% Improvement: Should Treatment Response Go Beyond Symptom Improvement When Evaluating the Treatment of Depression?

Mark Zimmerman, MD^a ; Sin-Ying Lin, PhD^a

J Clin Psychiatry 2023;84(3):22m14706

ABSTRACT

Background: The emphasis on symptom resolution in depression treatment research is at variance with the recommendations of official treatment guidelines and the results of surveys of depressed patients’ views of the most important treatment goals. In the present study, we examined the interrelationship between response rates on various outcome domains and whether response on each domain was associated with patients’ global rating of improvement (PGI) reported upon treatment completion. We also examined whether the PGI was associated with the number of domains on which the patients had achieved responder status and which domains were independent predictors of PGI response.

Methods: Between January 2016 to April 2022, 844 patients with DSM-IV major depressive disorder completed the Remission from Depression Questionnaire (RDQ), a self-report measure that assesses 6 constructs considered by patients to be relevant to assessing treatment outcome. The patients completed the RDQ at admission and discharge from the treatment program. For each domain, response was defined as a 50% or greater reduction in scores. At discharge, the patients rated the PGI.

Results: The patients significantly improved from admission to discharge on each of the 6 domains assessed on the RDQ (Cohen d range, 1.09–1.55). The responders on each domain reported significantly greater improvement on the global rating of improvement at discharge (all P values < .001). Responder status in one domain mostly co-occurred with responder status in another domain. In a logistic regression analysis, responses on all domains except nondepressive symptoms were independently associated with PGI response.

Conclusions: The results of the present study are consistent with the results of multiple patient surveys which have suggested that focusing on symptom reduction is too narrow of an approach when measuring outcome in the treatment of depression. Expanding the assessment of outcome beyond symptoms and viewing nonsymptomatic outcome domains as critical composites of primary endpoints would be more consistent with a patient-centered approach toward the treatment of depression.

Continue Reading...

Members enjoy unlimited free PDF downloads as part of their subscription! Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Buy PDF for $40

Please sign in or purchase this PDF for $40.

References (29)

US Food and Drug Administration, Center for Biologics Evaluations and Research. Guidance for Industry: Providing clinical evidence of effectiveness for human drugs and biological products. FDA website. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-clinical-evidence-effectiveness-human-drug-and-biological-products. May 1998.
US Food and Drug Administration. Major depressive disorder: developing drugs for treatment. Guidance for industry Docket No. FDA-2018-D-1919. FDA website. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/major-depressive-disorder-developing-drugs-treatment. 2018:28851–28853.
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–758. PubMed CrossRef
Cuijpers P, Noma H, Karyotaki E, et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92–107. PubMed CrossRef
Iovieno N, Papakostas GI. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2012;73(10):1300–1306. PubMed CrossRef
Rutherford BR, Cooper TM, Persaud A, et al. Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout. J Clin Psychiatry. 2013;74(7):703–715. PubMed CrossRef
Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? the depressed patient’s perspective. Am J Psychiatry. 2006;163(1):148–150. PubMed CrossRef
Demyttenaere K, Donneau AF, Albert A, et al. What is important in being cured from depression? discordance between physicians and patients (1). J Affect Disord. 2015;174:390–396. PubMed CrossRef
Baune BT, Christensen MC. Differences in perceptions of major depressive disorder symptoms and treatment priorities between patients and health care providers across the acute, post-acute, and remission phases of depression. Front Psychiatry. 2019;10:335. PubMed CrossRef
Holtforth MG, Wyss T, Schulte D, et al. Some like it specific: the difference between treatment goals of anxious and depressed patients. Psychol Psychother. 2009;82(Pt 3):279–290. PubMed CrossRef
Ramnerö J, Jansson B. Treatment goals and their attainment: a structured approach to assessment and evaluation. Cogn Behav Ther. 2016;9:E2. CrossRef
Uebelacker LA, Battle CL, Friedman MA, et al. The importance of interpersonal treatment goals for depressed inpatients. J Nerv Ment Dis. 2008;196(3):217–222. PubMed CrossRef
Zimmerman M, Martinez JH, Attiullah N, et al. A new type of scale for determining remission from depression: the Remission from Depression Questionnaire. J Psychiatr Res. 2013;47(1):78–82. PubMed CrossRef
Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
Zimmerman M, Galione JN, Attiullah N, et al. Depressed patients’ perspectives of two measures of outcome: The Quick Inventory of Depressive Symptomatology (QIDS) and the Remission from Depression Questionnaire (RDQ). Ann Clin Psychiatry. 2011;23(3):208–212. PubMed
Zimmerman M, Martinez JH, Attiullah N, et al. The remission from depression questionnaire as an outcome measure in the treatment of depression. Depress Anxiety. 2014;31(6):533–538. PubMed CrossRef
Jones R, Yates WR, Williams S, et al. Outcome for adjustment disorder with depressed mood: comparison with other mood disorders. J Affect Disord. 1999;55(1):55–61. PubMed CrossRef
First MB, Spitzer RL, Williams JBW, et al. Structured Clinical Interview for DSM-IV (SCID). Washington, D.C.: American Psychiatric Association; 1997.
Pfohl B, Blum N, Zimmerman M. Structured Interview for DSM-IV Personality. Washington, DC: American Psychiatric Press, Inc.; 1997.
Gelenberg AJ, Freeman MP, Markowitz JC, et al. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Washington, DC: American Psychiatric Association; 2010.
Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087–1206. PubMed CrossRef
Lam RW, McIntosh D, Wang J, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder, Section 1: disease burden and principles of care. Can J Psychiatry. 2016;61(9):510–523. PubMed CrossRef
IsHak WW, Greenberg JM, Balayan K, et al. Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry. 2011;19(5):229–239. PubMed CrossRef
Morton E, Foxworth P, Dardess P, et al. “Supporting Wellness”: a depression and bipolar support alliance mixed-methods investigation of lived experience perspectives and priorities for mood disorder treatment. J Affect Disord. 2022;299:575–584. PubMed CrossRef
Kan K, Jörg F, Buskens E, et al. Patients’ and clinicians’ perspectives on relevant treatment outcomes in depression: qualitative study. BJPsych Open. 2020;6(3):e44. PubMed CrossRef
Cuijpers P. Targets and outcomes of psychotherapies for mental disorders: an overview. World Psychiatry. 2019;18(3):276–285. PubMed CrossRef
Zimmerman M, Clark HL, Multach MD, et al. Have treatment studies of depression become even less generalizable?: a review of the inclusion and exclusion criteria in placebo controlled antidepressant efficacy trials published during the past 20 years. Mayo Clin Proc. 2015;90(9):1180–1186. PubMed CrossRef
Zimmerman M, Chelminski I, McDermut W. Major depressive disorder and Axis I diagnostic comorbidity. J Clin Psychiatry. 2002;63(3):187–193. PubMed CrossRef
Herrman H, Patel V, Kieling C, et al. Time for united action on depression: a Lancet–World Psychiatric Association Commission. Lancet. 2022;399(10328):957–1022. PubMed CrossRef